With the growing count of nonalcoholic steatohepatitis incidences, there is an increasing demand for nonalcoholic steatohepatitis therapeutics. This results in the launching of multiple drugs to cure the disease with the objective to provide relief. Owing to these factors, the nonalcoholic steatohepatitis therapeutics market is projected to experience tremendous growth opportunities in the upcoming years.
The increasing prevalence of obesity and diabetes leads to various damages to the liver. This factor is estimated to supplement the growth avenues in the market. Further, growing awareness among the populace about therapeutics is estimated to play a crucial role in expansion of the nonalcoholic steatohepatitis therapeutics market.
Nonalcoholic fatty liver diseases (NAFLD) may result in nonalcoholic steatohepatitis (NASH), which is a severe chronic situation. In order to avoid such conditions, the solutions from the nonalcoholic steatohepatitis therapeutics market are increasingly utilized globally.
The lack of appropriate diagnostic techniques and poor diagnostics are anticipated to curtail the expansion opportunities in the nonalcoholic steatohepatitis therapeutics market.
As per the research report by Transparency Market Research, the nonalcoholic steatohepatitis therapeutics market is estimated to expand at a CAGR of 10.7% during the forecast period from 2015 to 2025 and to reach the valuation of US$ 20.27 Bn by 2025.
Pioglitazone and Vitamin E Considered First Line Drugs in Nonalcoholic Steatohepatitis Therapeutics Market
Lifestyle intervention is considered as the starting step to manage the treatment of NASH. For the treatment of nonalcoholic steatohepatitis, there is an absence of FDA-approved medicine till now. The medical practitioners recommend pioglitazone and vitamin E, which have been considered as the first line drugs. Pioglitazone and vitamin E is considered as the prominent drug segment because of its high efficacy. Owing to this factor, these first line drugs are projected to create growth opportunities in the nonalcoholic steatohepatitis therapeutics market.
Selonsertrib & cenicriviroc, obeticholic acid (OCA), and elafibranor are some other segments of nonalcoholic steatohepatitis therapeutics market on the basis of drug type. Owing to effective treatment to NASH patients, elafibranor and seloncertib & ceniccriviroc drugs types are also estimated to show prominent growth in the market.
The expansion opportunities in the nonalcoholic steatohepatitis therapeutics market are also affected by the distribution channels. Retail pharmacy is anticipated to emerge as the leading contributor in market revenue on the back of the presence of retail pharmacies and drug stores around the world. Further, the onset of the online service provider segment is likely to contribute to the market growth.
Some of the key players operating in the nonalcoholic steatohepatitis therapeutics market include Immuron Ltd., Gilead Sciences, Inc., Zydus Cadila, Galmed Pharmaceuticals Ltd., Astazeneca Plc., Tobira Therapeutics, Inc., Conatus Pharmaceuticals, GENFIT SA, and Intercept Pharmaceuticals Inc. These market players along with new entrants are putting efforts for the development of more effective treatment solutions for NASH disease.
North America Projected to Hold Significant Position over Other Regions in Nonalcoholic Steatohepatitis Therapeutics Market
The nonalcoholic steatohepatitis therapeutics market is spread across various geographical regions including North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America. Among these, the North America and Europe regions are expected to hold a significant position in the market on the back of an increasing number of NASH patients due to the rising count of the diabetic and obese population. Further, changing lifestyles and increase in number of high cholesterol patients are also creating a fertile ground for growth of the regional market.
France, the UK, Germany, Spain, and Italy are some of the major countries in Europe that are experiencing an increased number of NASH cases. This factor is expected to bring prominent sales opportunities in the nonalcoholic steatohepatitis therapeutics market.
The global nonalcoholic steatohepatitis therapeutics (NASH) market is divided into:
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem-solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453